Danitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer


Prescrire International 22(138): 120

2013


ISSN/ISBN: 1167-7422
PMID: 23819169
Document Number: 671428
Adding panitumumab to standard protocols does not prolong survival but provokes additional adverse effects.

Document emailed within 1 workday
Secure & encrypted payments